BioWorld

Oct. 22, 2010

View Archived Issues

Metabolic Solutions Development Raises $23.5M in Series D Round

Genentech's Herceptin Wins U.S. OK in Stomach Cancer

Coming Monday in BioWorld Insight

Corrections & Clarifications

Other News To Note

Stock Movers

Earnings Roundup

Clinic Roundup

MacroGenics Looks to Pipeline After Teplizumab Phase III Miss

MacroGenics Inc. and partner Eli Lilly and Co.'s teplizumab failed to meet its primary efficacy endpoint in a Phase III trial for Type 1 diabetes. (BioWorld Today) Read More

Adverse Event Halts Cardiome's Confirmatory Kynapid AF Trial

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...